Anaplastic thyroid cancer: a comprehensive review of novel therapy

References

• Sherman SI. Thyroid carcinoma. Lancet361(9356), 501–511 (2003).
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer16(1), 17–44 (2009).
   PubMed Web of Science ®Google Scholar
• Pinchot SN, Sippel RS, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Ther. Clin. Risk Manag.4(5), 935–947 (2008).
   PubMedGoogle Scholar
• Wiseman SM, Masoudi H, Niblock P et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann. Surg. Oncol.14(2), 719–729 (2007).
   PubMed Web of Science ®Google Scholar
• Brignardello E, Gallo M, Baldi I et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur. J. Endocrinol.156(4), 425–430 (2007).
   PubMedGoogle Scholar
• Baroli A, Pedrazzini L, Lomuscio G, Marzoli L. Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from a 40-year experience at a single Italian institution. Minerva Endocrinol.35(1), 9–16 (2010).
   PubMedGoogle Scholar
• Chiacchio S, Lorenzoni A, Boni G et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol.33(4), 341–357 (2008).
   PubMed Web of Science ®Google Scholar
• Stenner F, Liewen H, Zweifel M et al. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci.99(9), 1847–1852 (2008).
   PubMedGoogle Scholar
• Moretti F, Farsetti A, Soddu S et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene14(6), 729–740 (1997).
   PubMed Web of Science ®Google Scholar
• Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med. Chem.7(3), 359–365 (2007).
   PubMed Web of Science ®Google Scholar
• Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol.5(7), 419–429 (2004).
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Ferrari SM et al. Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J. Clin. Endocrinol. Metab.91(2), 614–620 (2006).
   PubMed Web of Science ®Google Scholar
• Miccoli P, Materazzi G, Antonelli A et al. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch. Surg.392(4), 397–404 (2007).
   PubMed Web of Science ®Google Scholar
• Wiseman SM, Masoudi H, Niblock P et al. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am. J. Surg.191(5), 581–587 (2006).
   PubMed Web of Science ®Google Scholar
• Wiseman SM, Loree TR, Hicks WL Jr et al. Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction. Arch. Otolaryngol. Head Neck Surg.129(1), 96–100 (2003).
   PubMedGoogle Scholar
• Wiseman SM, Loree TR, Rigual NR et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck25(8), 662–670 (2003).
   PubMedGoogle Scholar
• Wiseman SM, Griffith OL, Deen S et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch. Surg.142(8), 717–727 (2007).
   PubMedGoogle Scholar
• Antonelli A, Fallahi P, Ferrari SM et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed. Pharmacother.62(8), 559–563 (2008).
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab.93(11), 4331–4341 (2008).
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin. Endocrinol.69(1), 148–152 (2008).
   PubMed Web of Science ®Google Scholar
• Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clin. Prac.2(1), 42–52 (2006).
   Google Scholar
• Gupta -Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol.26(29), 4714–4719 (2008).
   PubMedGoogle Scholar
• Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J. Clin. Oncol.26(29), 4708–4713 (2008).
   PubMed Web of Science ®Google Scholar
• Volante M, Rapa I, Papotti M. Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocrine Pathol.19(3), 150–155 (2008).
   PubMedGoogle Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev.28(7), 742–762 (2007).
   PubMed Web of Science ®Google Scholar
• Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Prac. Res.22(6), 955–969 (2008).
   Google Scholar
• Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Current Opin. Cell Biol.21(2), 296–303 (2009).
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Negri J, McMullan C et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol. Cancer Ther.6(3), 1070–1078 (2007).
   PubMedGoogle Scholar
• Ball DW, Jin N, Rosen DM et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J. Clin. Endocrinol. Metab.92(12), 4712–4718 (2007).
   PubMed Web of Science ®Google Scholar
• Kim S, Yazici YD, Calzada G et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol. Cancer Ther.6(6), 1785–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Sala E, Mologni L, Truffa S et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res.6(5), 751–759 (2008).
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Kerege AA, Sharma V et al. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen–activated protein kinase kinase 1/2 inhibition. Thyroid19(8), 825–835 (2009).
   PubMedGoogle Scholar
• Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr. Relat. Cancer14(4), 957–977 (2007).
   PubMedGoogle Scholar
• Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol. Metab. Clin. North Am.37(2), 375–387, viii–ix (2008).
   PubMedGoogle Scholar
• Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr. Biol.17(8), R280–R283 (2007).
   PubMedGoogle Scholar
• Nappi TC, Salerno P, Zitzelsberger H et al. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res.69(5), 1916–1923 (2009).
   PubMedGoogle Scholar
• Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature369(6483), 756–758 (1994).
   PubMed Web of Science ®Google Scholar
• Papewalis C, Wuttke M, Schinner S et al. Role of the Novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm. Metab. Res.41(10), 752–756 (2009).
   PubMedGoogle Scholar
• Oudard S, Medioni J, Aylllon J et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther.9(6), 705–717 (2009).
   PubMed Web of Science ®Google Scholar
• Ensinger C, Spizzo G, Moser P et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. NY Acad. Sci.1030, 69–77 (2004).
   PubMedGoogle Scholar
• Mitsiades CS, Kotoula V, Poulaki V et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J. Clin. Endocrinol. Metab.91(9), 3662–3666 (2006).
   PubMed Web of Science ®Google Scholar
• Sun L, Liang C, Shirazian S et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem.46(7), 1116–1119 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffmann S, Burchert A, Wunderlich A et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine31(2), 105–113 (2007).
   PubMedGoogle Scholar
• Kim S, Prichard CN, Younes MN et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res.12(2), 600–607 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez JP, Wang-Rodriguez J, Chang CY et al. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope118(8), 1372–1376 (2008).
   PubMed Web of Science ®Google Scholar
• Lopez JP, Wang–Rodriguez J, Chang C et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch. Otolaryngol. Head Neck Surg.133(10), 1022–1027 (2007).
   PubMed Web of Science ®Google Scholar
• Hogan T, Jing Jie Y, Williams HJ et al. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J. Oncol. Pharm. Pract.15(2), 111–117 (2009).
   PubMedGoogle Scholar
• Pennell NA, Daniels GH, Haddad RI et al. A Phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid18(3), 317–323 (2008).
   PubMed Web of Science ®Google Scholar
• Fury MG, Solit DB, Su YB et al. A Phase I trial of intermittent high–dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol.59(4), 467–475 (2007).
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Kerege AA, French JD et al. Inhibition of Src with AZD0530 reveals the Src–Focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab.94(6), 2199–2203 (2009).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med.7(9), 987–989 (2001).
   PubMed Web of Science ®Google Scholar
• O’Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M. Anaplastic thyroid cancer, tumorigenesis and therapy. Irish J. Med. Sci.179(1), 9–15 (2010).
   PubMedGoogle Scholar
• Prichard CN, Kim S, Yazici YD et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope117(4), 674–679 (2007).
   PubMedGoogle Scholar
• Gomez–Rivera F, Santillan–Gomez AA, Younes MN et al. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin. Cancer Res.13(15 Pt 1), 4519–4527 (2007).
   PubMed Web of Science ®Google Scholar
• Kim S, Schiff BA, Yigitbasi OG et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol. Cancer Ther.4(4), 632–640 (2005).
   PubMedGoogle Scholar
• Cooney MM, Ortiz J, Bukowski RM, Remick SC. Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr. Oncol. Rep.7(2), 90–95 (2005).
   PubMedGoogle Scholar
• Mooney CJ, Nagaiah G, Fu P et al. A Phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid19(3), 233–240 (2009).
   PubMed Web of Science ®Google Scholar
• Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol. Metab. Clin. North Am.37(2), 511–524, xi (2008).
   PubMedGoogle Scholar
• Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr. Pract.15(6), 605–611 (2009).
   PubMed Web of Science ®Google Scholar
• Fuente N, Mane JM, Barcelo R et al. Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Ann. Oncol.15(3), 537 (2004).
   PubMed Web of Science ®Google Scholar
• Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid17(7), 663–670 (2007).
   PubMed Web of Science ®Google Scholar
• Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann. Surg.231(3), 329–338 (2000).
   PubMedGoogle Scholar
• Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg. Oncol.12(2), 69–90 (2003).
   PubMedGoogle Scholar
• Ulisse S, Delcros JG, Baldini E et al. Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int. J. Cancer119(2), 275–282 (2006).
   PubMed Web of Science ®Google Scholar
• Arlot–Bonnemains Y, Baldini E, Martin B et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr. Relat. Cancer15(2), 559–568 (2008).
   PubMed Web of Science ®Google Scholar
• Moretti F, Nanni S, Farsetti A et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J. Clin. Endocrinol. Metab.85(1), 302–308 (2000).
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Yokoi H, Takeda K et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J. Clin. Endocrinol. Metab.85(11), 4081–4086 (2000).
   PubMed Web of Science ®Google Scholar
• Pacifico F, Leonardi A. Role of NF-κB in thyroid cancer. Mol. Cell Endocrinol. (2009).
   PubMedGoogle Scholar
• Meng Z, Mitsutake N, Nakashima M et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology149(11), 5357–5365 (2008).
   PubMedGoogle Scholar
• Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol.14(10), 2534–2543 (2003).
   PubMed Web of Science ®Google Scholar
• Iannetti A, Pacifico F, Acquaviva R et al. The neutrophil gelatinase–associated lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl Acad. Sci. USA105(37), 14058–14063 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu W, Ou Y, Li Y et al. A small–molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-κB pathway. Mol. Pharmacol.75(4), 812–819 (2009).
   PubMedGoogle Scholar
• Festa M, Petrella A, Alfano S, Parente L. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-κB pathway. Int. J. Cancer124(11), 2728–2736 (2009).
   PubMed Web of Science ®Google Scholar
• Bonofiglio D, Qi H, Gabriele S et al. Peroxisome proliferator-activated receptor γ inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr. Relat. Cancer15(2), 545–557 (2008).
   PubMedGoogle Scholar
• Antonelli A, Ferrari SM, Fallahi P et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol.159(3), 283–291 (2008).
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin. Endocrinol.70(6), 946–953 (2009).
   PubMed Web of Science ®Google Scholar
• Hayashi N, Nakamori S, Hiraoka N et al. Antitumor effects of peroxisome proliferator activate receptor γ ligands on anaplastic thyroid carcinoma. Int. J. Oncol.24(1), 89–95 (2004).
   PubMed Web of Science ®Google Scholar
• Su W, Necela BM, Fujiwara K et al. The high affinity peroxisome proliferator-activated receptor-γ agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. Int. J. Cancer123(5), 991–997 (2008).
   PubMed Web of Science ®Google Scholar
• Marlow LA, Reynolds LA, Cleland AS et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res.69(4), 1536–1544 (2009).
   PubMed Web of Science ®Google Scholar
• Shimazaki N, Togashi N, Hanai M et al. Anti-tumour activity of CS–7017, a selective peroxisome proliferator-activated receptor γ agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur. J. Cancer44(12), 1734–1743 (2008).
   PubMed Web of Science ®Google Scholar
• Park JW, Zarnegar R, Kanauchi H et al. Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid15(3), 222–231 (2005).
   PubMed Web of Science ®Google Scholar
• Philips JC, Petite C, Willi JP, Buchegger F, Meier CA. Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nuclear Med. Comm.25(12), 1183–1186 (2004).
   PubMed Web of Science ®Google Scholar
• Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov.6(10), 793–810 (2007).
   PubMed Web of Science ®Google Scholar
• Jeong H, Kim YR, Kim KN et al. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nuclear Med. Biol.33(7), 875–882 (2006).
   PubMedGoogle Scholar
• Lan L, Cui D, Luo Y et al. Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro. J. Endocrinol. Invest.32(9), 731–738 (2009).
   PubMedGoogle Scholar
• Rigas JR, Dragnev KH. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist10(1), 22–33 (2005).
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Assaf C, Bagot M et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br. J. Dermatol.157(3), 433–440 (2007).
   PubMed Web of Science ®Google Scholar
• Klopper JP, Berenz A, Hays WR et al. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin. Cancer Res.14(2), 589–596 (2008).
   PubMedGoogle Scholar
• Gruning T, Tiepolt C, Zophel K et al. Retinoic acid for redifferentiation of thyroid cancer – does it hold its promise? Eur. J. Endocrinol.148(4), 395–402 (2003).
   PubMedGoogle Scholar
• Short SC, Suovuori A, Cook G, Vivian G, Harmer C. A Phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin. Oncol.16(8), 569–574 (2004).
   PubMed Web of Science ®Google Scholar
• Du ZX, Wang HQ, Zhang HY, Gao DX. Involvement of glyceraldehyde-3-phosphate dehydrogenase in tumor necrosis factor-related apoptosis-inducing ligand-mediated death of thyroid cancer cells. Endocrinology148(9), 4352–4361 (2007).
   PubMed Web of Science ®Google Scholar
• Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin–proteasome system for cancer therapy. Cancer Sci.100(1), 24–28 (2009).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med.348(26), 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Conticello C, Adamo L, Giuffrida R et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J. Clin. Endocrinol. Metab.92(5), 1938–1942 (2007).
   PubMedGoogle Scholar
• Takakura S, Mitsutake N, Nakashima M et al. Oncogenic role of miR-17–92 cluster in anaplastic thyroid cancer cells. Cancer Sci.99(6), 1147–1154 (2008).
   PubMed Web of Science ®Google Scholar
• Lin SF, Gao SP, Price DL et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin. Cancer Res.14(5), 1519–1528 (2008).
   PubMed Web of Science ®Google Scholar
• Reddi HV, Madde P, Reichert-Eberhardt AJ et al. ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Ther.15(11), 750–757 (2008).
   PubMedGoogle Scholar
• Libertini S, Iacuzzo I, Perruolo G et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922–947. Clin. Cancer Res.14(20), 6505–6514 (2008).
   PubMed Web of Science ®Google Scholar
• Lin SF, Yu Z, Riedl C et al. Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery142(6), 976–983 (2007).
   PubMed Web of Science ®Google Scholar
• Lin SF, Price DL, Chen CH et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J. Clin. Endocrinol. Metab.93(11), 4403–4407 (2008).
   PubMed Web of Science ®Google Scholar
• Abbosh PH, Li X, Li L et al. A conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Ther.14(4), 399–408 (2007).
   PubMed Web of Science ®Google Scholar
• Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. Mol. Asp. Med.31(2), 215–226 (2010).
   PubMed Web of Science ®Google Scholar
• Catalano MG, Pugliese M, Poli R et al. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol. Rep.21(2), 515–521 (2009).
   PubMedGoogle Scholar
• Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer14(3), 839–845 (2007).
   PubMed Web of Science ®Google Scholar
• Catalano MG, Fortunati N, Pugliese M et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol.191(2), 465–472 (2006).
   PubMed Web of Science ®Google Scholar
• Catalano MG, Fortunati N, Pugliese M et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab.90(3), 1383–1389 (2005).
   PubMed Web of Science ®Google Scholar
• Noguchi H, Yamashita H, Murakami T et al. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocrine J.56(2), 245–249 (2009).
   PubMed Web of Science ®Google Scholar
• Dowlati A, Robertson K, Cooney M et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res.62(12), 3408–3416 (2002).
   PubMed Web of Science ®Google Scholar
• Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr. Opin. Oncol.20(1), 19–24 (2008).
   PubMedGoogle Scholar
• Rovere RK, Awada A. Treatment of recurrent thyroid cancers – is there a light in the horizon? Curr. Opin. Oncol.20(3), 245–248 (2008).
   PubMedGoogle Scholar
• Wardley AM, Pivot X, Morales-Vasquez F et al. Randomized Phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J. Clin. Oncol.28(6), 976–983 (2009).
   PubMedGoogle Scholar
• Woyach JA, Shah MH. New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer16(3), 715–731 (2009).
   PubMedGoogle Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26(10), 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Shendure J, Stewart CJ. Cancer genomes on a shoestring budget. N. Engl. J. Med.360(26), 2781–2783 (2009).
   PubMed Web of Science ®Google Scholar
• Holt RA, Jones SJ. The new paradigm of flow cell sequencing. Genome Res.18(6), 839–846 (2008).
   PubMed Web of Science ®Google Scholar
• Papewalis C, Ehlers M, Schott M. Advances in cellular therapy for the treatment of thyroid cancer. J. Oncol.2010, 179491 (2010).
   PubMedGoogle Scholar
• Landriscina M, Maddalena F, Fabiano A et al. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res.30(2), 473–480 (2010).
   PubMedGoogle Scholar
• Landriscina M, Piscazzi A, Fabiano A et al. Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. Thyroid19(6), 629–637 (2009).
   PubMedGoogle Scholar
• Kurebayashi J, Okubo S, Yamamoto Y et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother. Pharmacol.58(4), 460–470 (2006).
   PubMedGoogle Scholar
• Yeung SC, She M, Yang H et al. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab.92(8), 2902–2909 (2007).
   PubMed Web of Science ®Google Scholar
• Gregorc V, Santoro A, Bennicelli E et al. Phase Ib study of NGR- hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br. J. Cancer101(2), 219–224 (2009).
   PubMed Web of Science ®Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol.26(22), 3709–3714 (2008).
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol.28(14), 2323–2330 (2010).
   PubMed Web of Science ®Google Scholar